Compare Novavax Inc (NVAX) vs Prudential PLC (PUK) Price & Performance

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Prudential PLC (PUK) trades at $27.495, down 2.57% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and robust cash flow from operations of $3.61B in 2024. Recent earnings beat expectations in Q4 2025, though Q4 2024 missed. The stock faces headwinds from China regulatory news impacting Asian operations, but analyst consensus remains 50% buy.

The outlook is mixed: attractive valuation and profitability support upside, but regulatory risks in China and bearish technicals pose near-term challenges. Investors should weigh strong cash generation and earnings beats against geopolitical exposures and market sentiment pressures for balanced risk-reward assessment.